<bill session="117" type="h" number="5463" updated="2023-02-17T18:00:24Z">
  <state datetime="2021-09-30">REFERRED</state>
  <status>
    <introduced datetime="2021-09-30"/>
  </status>
  <introduced datetime="2021-09-30"/>
  <titles>
    <title type="display">Drug Pricing Transparency and Accountability Act</title>
    <title type="official" as="introduced">To increase reporting requirements and transparency requirements in the 340B Drug Pricing Program, and for other purposes.</title>
    <title type="short" as="introduced">Drug Pricing Transparency and Accountability Act</title>
  </titles>
  <sponsor bioguide_id="R000103"/>
  <cosponsors/>
  <actions>
    <action datetime="2021-09-30">
      <text>Introduced in House</text>
    </action>
    <action datetime="2021-09-30" state="REFERRED">
      <text>Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.</text>
    </action>
    <action datetime="2021-09-30">
      <text>Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.</text>
    </action>
    <action datetime="2021-10-01">
      <text>Referred to the Subcommittee on Health.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" subcommittee="" activity="Referral"/>
    <committee code="HSIF14" name="House Energy and Commerce" subcommittee="Health" activity="Referral"/>
    <committee code="HSWM" name="House Ways and Means" subcommittee="" activity="Referral"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
    <term name="Administrative law and regulatory procedures"/>
    <term name="Congressional oversight"/>
    <term name="Department of Health and Human Services"/>
    <term name="Government information and archives"/>
    <term name="Government studies and investigations"/>
    <term name="Health facilities and institutions"/>
    <term name="Health information and medical records"/>
    <term name="Home and outpatient care"/>
    <term name="Hospital care"/>
    <term name="Medicaid"/>
    <term name="Medicare"/>
    <term name="Prescription drugs"/>
    <term name="Public contracts and procurement"/>
    <term name="Public-private cooperation"/>
    <term name="State and local government operations"/>
  </subjects>
  <amendments/>
  <summary date="2022-04-08T22:55:53Z" status="Introduced in House">Drug Pricing Transparency and Accountability Act

This bill establishes a two-year moratorium on allowing new, non-rural hospitals and associated child sites to participate in the 340B drug pricing program; during the moratorium, the Department of Health and Human Services must issue regulations with specified program eligibility standards. The bill also requires additional reporting relating to program participation, eligibility, and costs.</summary>
</bill>
